Notice: This company has been marked as potentially delisted and may not be actively trading. Cerevel Therapeutics (CERE) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period The Vistria Group Announces the Appointment of Healthcare Pioneer Dr. Tony Coles as Senior AdvisorFebruary 20 at 11:44 AM | finance.yahoo.comCeres stock tumbles after Bosch ends partnershipFebruary 20 at 6:04 AM | investing.comOptimistic Buy Rating for Ceres Power Holdings Amid Bosch Partnership ChangesFebruary 20 at 3:38 AM | tipranks.comCeres Power Maintains Confidence as Bosch Ends PartnershipFebruary 20 at 2:12 AM | tipranks.comCeres Global Ag GAAP EPS of -$0.01, revenue of $219.9MFebruary 13, 2025 | seekingalpha.comCERE Investors Have Opportunity to Join Cerevel Therapeutics Holdings, Inc. Fraud Investigation with the Schall Law FirmFebruary 13, 2025 | prnewswire.comCERE Investors Have Opportunity to Join Cerevel Therapeutics Holdings, Inc. Fraud Investigation with the Schall Law FirmFebruary 12, 2025 | businesswire.comParkinson’s Disease Market is anticipated to Grow at a CAGR of 5.8% During the Study Period (2020-2034) by DelveInsightFebruary 8, 2025 | theglobeandmail.comAstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trialFebruary 7, 2025 | msn.comAnalysts reset AbbVie stock price target after earningsFebruary 4, 2025 | msn.comAbbVie swings to Q4 loss amid Cerevel impact; sets in-line guidanceJanuary 31, 2025 | msn.comCeres Power Announces Total Voting Rights UpdateJanuary 31, 2025 | tipranks.comCeres Power CFO Increases Stake in CompanyJanuary 30, 2025 | tipranks.comSector Spotlight: Big Pharma will push to pause Medicare drug price negotiationsJanuary 18, 2025 | markets.businessinsider.comAbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?January 16, 2025 | finance.yahoo.comAbbVie plans to 'commit less capital' towards psychiatric drugs, CEO saysJanuary 15, 2025 | msn.comAbbVie CEO says psychiatric drug space challenging, more cautious on investmentsJanuary 15, 2025 | msn.comBlueRock accelerates Parkinson’s disease therapy to Phase IIIJanuary 14, 2025 | msn.comCeres Power Applies for Block Listing on LSE to Boost GrowthJanuary 14, 2025 | tipranks.comAbbVie secures option to license Simcere's blood cancer drug candidateJanuary 13, 2025 | msn.comHealth Care Down on Defensive Bias -- Health Care RoundupJanuary 11, 2025 | marketwatch.comAbbVie sees $3.5B impairment charge related to emraclidineJanuary 11, 2025 | markets.businessinsider.comAbbVie to record $3.5B impairment charge for Cerevel drugJanuary 11, 2025 | msn.comAbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia DrugJanuary 10, 2025 | msn.comCompanies sold a record $8 trillion of bonds last year amid high demand and lower borrowing costsJanuary 3, 2025 | msn.comGlobal corporate borrowing climbs to record $8tn in 2024December 27, 2024 | ft.comTerragen Holdings Sees Shift as Ceres Capital ExitsDecember 18, 2024 | tipranks.comAbbVie Stock Volatile On $200M Deal To Buy Nimble Therapeutics: Retail Still BearishDecember 13, 2024 | msn.comHope for Parkinson’s disease symptoms is found in late-stage drug studyDecember 10, 2024 | msn.comIs AbbVie Stock Underperforming the Dow?December 9, 2024 | msn.comAbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study -- UpdateDecember 9, 2024 | marketwatch.comAbbVie's Parkinson's disease drug improves patient mobility in late-stage studyDecember 9, 2024 | msn.comFrom Cobenfy to Emraclidine: the muscarinic path to safer antipsychoticsDecember 3, 2024 | finance.yahoo.comCeres Power Director Buys Shares, Boosting Green Energy FocusNovember 28, 2024 | tipranks.comAbbVie Tumbles After New Schizophrenia Drug Fails Two TrialsNovember 11, 2024 | finance.yahoo.comAbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock SurgesNovember 11, 2024 | benzinga.comAbbVie's closely watched schizophrenia drug fails two studies, shares slideNovember 11, 2024 | msn.comRapport Therapeutics adds new members to Board of DirectorsNovember 8, 2024 | markets.businessinsider.comAbbVie Inc (ABBV) Q3 2024 Earnings Call Highlights: Strong Growth in Ex-Humira Platform and ...November 1, 2024 | finance.yahoo.comAbbVie Inc. (NYSE:ABBV) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | msn.comAbbVie (ABBV) Q3 2024 Earnings Call TranscriptOctober 30, 2024 | msn.comAbbVie to buy Alzheimer's therapy developer Aliada for US$1.4 billionOctober 28, 2024 | msn.comAbbVie lowers first-quarter guidance after closing acquisition ImmunoGenOctober 14, 2024 | msn.comMindfulness Meditation Similar to Antidepressant for Reducing Anxiety SymptomsOctober 11, 2024 | msn.comAbbVie: A Strong Investment Opportunity In Neurological And Oncology BreakthroughsOctober 3, 2024 | seekingalpha.comAbbVie's Emraclidine: M4 Agonist Might Become Best-In-Class In SchizophreniaOctober 3, 2024 | seekingalpha.comKailera Therapeutics nets $400 million as weight-loss drug market heats upOctober 2, 2024 | msn.comAbbVie Inc. (ABBV) Projects Mid-Single-Digit Sales Growth Over Next 3 YearsSeptember 30, 2024 | msn.comHalf Year 2024 Ceres Power Holdings PLC Earnings Presentation TranscriptSeptember 30, 2024 | gurufocus.com8 Best Inexpensive Stocks To Invest In NowSeptember 27, 2024 | insidermonkey.com Get Cerevel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter. Email Address CERE Media Mentions By Week CERE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CERE News Sentiment▼0.000.60▲Average Medical News Sentiment CERE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CERE Articles This Week▼43▲CERE Articles Average Week Get Cerevel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CNX Resources News Today Warrior Met Coal News Today Core Natural Resources News Today Hallador Energy News Today Royalty Pharma News Today Teva Pharmaceutical Industries News Today United Therapeutics News Today Summit Therapeutics News Today Insmed News Today Genmab A/S News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CERE) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerevel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
